JP2014507421A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014507421A5 JP2014507421A5 JP2013551282A JP2013551282A JP2014507421A5 JP 2014507421 A5 JP2014507421 A5 JP 2014507421A5 JP 2013551282 A JP2013551282 A JP 2013551282A JP 2013551282 A JP2013551282 A JP 2013551282A JP 2014507421 A5 JP2014507421 A5 JP 2014507421A5
- Authority
- JP
- Japan
- Prior art keywords
- conr
- alkyl
- cycloalkyl
- ring
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 5
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 2
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- -1 CF 3 Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical group [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000011287 therapeutic dose Methods 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161436077P | 2011-01-25 | 2011-01-25 | |
| US61/436,077 | 2011-01-25 | ||
| PCT/US2012/022315 WO2012103059A2 (en) | 2011-01-25 | 2012-01-24 | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014507421A JP2014507421A (ja) | 2014-03-27 |
| JP2014507421A5 true JP2014507421A5 (https=) | 2016-01-28 |
| JP5998152B2 JP5998152B2 (ja) | 2016-09-28 |
Family
ID=46544312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013551282A Active JP5998152B2 (ja) | 2011-01-25 | 2012-01-24 | Ｂｃｌ−２／ｂｃｌ−ｘｌ阻害剤およびそれを使用する治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8691184B2 (https=) |
| EP (2) | EP2668180B1 (https=) |
| JP (1) | JP5998152B2 (https=) |
| KR (1) | KR101762724B1 (https=) |
| CN (1) | CN103562202B (https=) |
| AU (1) | AU2012209295B2 (https=) |
| CA (1) | CA2825306C (https=) |
| ES (1) | ES2693107T3 (https=) |
| SG (1) | SG192126A1 (https=) |
| WO (1) | WO2012103059A2 (https=) |
| ZA (1) | ZA201305571B (https=) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102318204B1 (ko) * | 2013-01-16 | 2021-10-26 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Bcl-2bcl-xl 억제제 및 그를 사용하는 치료 방법 |
| CN105377289A (zh) | 2013-04-21 | 2016-03-02 | 耶达研究及发展有限公司 | 用于下调Bcl-xL和/或Bcl-w的活性和/或量的试剂 |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| AU2015211021B2 (en) | 2014-01-28 | 2020-07-02 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| CN105753814A (zh) * | 2015-01-01 | 2016-07-13 | 成都贝斯凯瑞生物科技有限公司 | 取代氮杂环衍生物及其应用 |
| CA2981753A1 (en) * | 2015-02-06 | 2016-08-11 | Unity Biotechnology, Inc. | Compounds and uses in treatment of senescence-associated conditions |
| EP3261612A1 (en) | 2015-02-26 | 2018-01-03 | Yeda Research and Development Co. Ltd | Method of promoting hair growth |
| AU2016304856B8 (en) | 2015-08-10 | 2021-02-18 | Dana-Farber Cancer Institute, Inc. | Mechanism of resistance to BET bromodomain inhibitors |
| JP6936498B2 (ja) | 2016-04-21 | 2021-09-15 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ | 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用 |
| CN106177955B (zh) * | 2016-08-18 | 2018-03-16 | 广州威溶特医药科技有限公司 | Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| EP3441069B1 (en) | 2017-08-11 | 2023-04-05 | Unity Biotechnology, Inc. | Treatment of diabetic retinopathy using pharmaceutical agents that eliminate senescent cells |
| WO2019033122A1 (en) * | 2017-08-11 | 2019-02-14 | Unity Biotechnology, Inc. | TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
| US20200354336A9 (en) | 2017-08-11 | 2020-11-12 | Unity Biotechnology, Inc. | Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells |
| CN107573256B (zh) * | 2017-09-26 | 2020-02-21 | 安徽国星生物化学有限公司 | 一种对氯苯肼盐酸盐连续化生产方法及其装置 |
| US10588916B2 (en) | 2017-10-31 | 2020-03-17 | Unity Biotechnology, Inc. | Technology to inhibit vascular changes that lead to vision loss in the eye |
| CN109718377B (zh) * | 2017-10-31 | 2021-03-26 | 中国科学院脑科学与智能技术卓越创新中心 | KPNB1抑制剂和Bcl-xL抑制剂在制备抗肿瘤药物中的应用 |
| CA3043103C (en) | 2017-12-30 | 2021-02-09 | Unity Biotechnology | Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer |
| EP3737681A4 (en) | 2018-01-10 | 2022-01-12 | Recurium IP Holdings, LLC | BENZAMIDE COMPOUNDS |
| US10111873B1 (en) | 2018-01-17 | 2018-10-30 | King Saud University | Dihydropyrimidinone derivatives |
| EP3743069B1 (en) | 2018-01-22 | 2025-08-06 | BioVentures, LLC | Bcl-2 proteins degraders for cancer treatment |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| SI3788042T1 (sl) | 2018-04-29 | 2025-06-30 | Beigene Switzerland Gmbh | Zaviralci BCL-2 |
| JP7080346B2 (ja) | 2018-04-30 | 2022-06-03 | ユニティ バイオテクノロジー インコーポレイテッド | 老化細胞によって引き起こされるかまたは媒介される状態の臨床管理における使用のためおよびがんを治療するための、Ｂｃｌファミリーアンタゴニストであるホスホノアミダート |
| CA3056878C (en) | 2018-04-30 | 2021-03-30 | Unity Biotechnology | Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| US10738042B2 (en) | 2018-04-30 | 2020-08-11 | Unity Biotechnology, Inc. | Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| US10717722B2 (en) | 2018-06-13 | 2020-07-21 | Unity Biotechnology, Inc. | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CA3094449C (en) | 2018-07-31 | 2023-02-28 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases |
| CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| US12083136B2 (en) * | 2018-07-31 | 2024-09-10 | Ascentage Pharma (Suzhou) Co., Ltd | Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof |
| JP2021516262A (ja) | 2018-07-31 | 2021-07-01 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | リツキシマブ及び／若しくはベンダムスチンと組み合わされたＢｃｌ−２阻害剤又はＣＨＯＰと組み合わされたＢｃｌ−２阻害剤の相乗的な抗腫瘍効果 |
| TWI725488B (zh) | 2018-07-31 | 2021-04-21 | 大陸商蘇州亞盛藥業有限公司 | Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途 |
| US12220419B2 (en) | 2018-08-22 | 2025-02-11 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| JP2021535113A (ja) * | 2018-08-22 | 2021-12-16 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Jiangsu Hengrui Medicine Co., Ltd. | ピロロ−アミノ−ピリダジノン化合物およびその中間体の調製方法 |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| EP3906235B1 (en) * | 2019-01-04 | 2023-03-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Method for preparing sulfonamides drugs |
| US11370807B2 (en) | 2019-01-04 | 2022-06-28 | Ascentage Pharma (Suzhou) Co., Ltd. | Process for preparing sulfonamide compounds |
| TWI770503B (zh) * | 2019-05-13 | 2022-07-11 | 大陸商蘇州亞盛藥業有限公司 | 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物 |
| WO2021066873A1 (en) | 2019-10-03 | 2021-04-08 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
| WO2021133862A1 (en) * | 2019-12-24 | 2021-07-01 | The Regents Of The University Of California | Targeting the intrinsic apoptotic machinery in glioblastoma |
| US12552784B2 (en) | 2019-12-27 | 2026-02-17 | Newave Pharmaceutical Inc. | 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| EP3914257B1 (en) * | 2020-04-10 | 2023-12-27 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of a bcl-2/bcl-xl inhibitor with osimertinib |
| JP7839962B2 (ja) | 2020-04-15 | 2026-04-03 | ビーワン メディシンズ ワン ゲーエムベーハー | Ｂｃｌ－２阻害剤 |
| EP4146649A4 (en) * | 2020-05-08 | 2024-09-11 | Fochon Biosciences, Ltd. | COMPOUNDS AS BCL-2 INHIBITORS |
| US20250319183A1 (en) | 2021-04-07 | 2025-10-16 | David Avigan | Compositions and methods for the treatment of cancer |
| CA3230314A1 (en) * | 2021-08-31 | 2023-03-09 | Beigene Switzerland Gmbh | Solid forms of bcl-2 inhibitors, method of preparation, and use thereof |
| WO2023122000A1 (en) * | 2021-12-20 | 2023-06-29 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2024051741A1 (zh) * | 2022-09-06 | 2024-03-14 | 西藏海思科制药有限公司 | 一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用 |
| CN115557846B (zh) * | 2022-10-17 | 2023-11-10 | 成都道合尔医药技术有限公司 | 8-氨基辛酸的合成方法 |
| EP4719408A1 (en) * | 2023-05-30 | 2026-04-08 | Ascentage Pharma (Suzhou) Co., Ltd. | Bcl-2/bcl-xl protein degrader and use thereof |
| CN117756811A (zh) * | 2023-12-29 | 2024-03-26 | 贵州民族大学 | 一种合成多取代基吡咯化合物的方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0201475A2 (hu) * | 1999-02-09 | 2003-10-28 | 3-Dimensional Pharmaceuticals, Inc. | Heteroarilamidin-, metilamidin- és guanidinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények |
| US7432304B2 (en) | 2001-05-30 | 2008-10-07 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
| JP4898458B2 (ja) * | 2004-02-12 | 2012-03-14 | トランス テック ファーマ，インコーポレイテッド | 置換アゾール誘導体、組成物及び使用方法 |
| WO2005090297A1 (en) * | 2004-03-19 | 2005-09-29 | Biotie Therapies Corporation | Sulphonamide derivatives |
| EP1778206A4 (en) * | 2004-08-20 | 2009-08-05 | Univ Michigan | SMALL MOLECULE INHIBITORS FROM MEMBERS OF THE ANTIOPTOTIC BCL-2 FAMILY AND USES THEREOF |
| CA2577752A1 (en) * | 2004-08-20 | 2006-03-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| EP1888550B1 (en) * | 2005-05-12 | 2014-06-25 | AbbVie Bahamas Ltd. | Apoptosis promoters |
| JP5193861B2 (ja) * | 2005-07-07 | 2013-05-08 | アボット・ラボラトリーズ | アポトーシス促進剤 |
| JP2009515997A (ja) | 2005-11-18 | 2009-04-16 | タケダ サン ディエゴ インコーポレイテッド | グルコキナーゼ活性剤 |
| WO2007087441A2 (en) * | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Substituted aromatic compounds for inflammation and immune-related uses |
| MX2009000395A (es) * | 2006-07-14 | 2009-01-29 | Chemocentryx Inc | Triazolil fenil bencenosulfonamidas. |
| PE20080948A1 (es) * | 2006-07-25 | 2008-09-10 | Irm Llc | Derivados de imidazol como moduladores de la senda de hedgehog |
| EP2120580B1 (en) * | 2007-02-02 | 2017-12-27 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
| US7776877B2 (en) * | 2007-06-22 | 2010-08-17 | Chemocentryx, Inc. | N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides |
| UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| SI2324008T1 (sl) | 2008-07-24 | 2012-08-31 | Nerviano Medical Sciences Srl | 3,4-diarilpirazoli kot protein-kinazni inhibitorji |
| US20110319392A1 (en) * | 2009-03-12 | 2011-12-29 | George Adjabeng | Thiazole Sulfonamide And Oxazole Sulfonamide Kinase Inhibitors |
| US20100278921A1 (en) | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| WO2011029842A1 (en) * | 2009-09-10 | 2011-03-17 | Novartis Ag | Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer |
-
2012
- 2012-01-24 SG SG2013056544A patent/SG192126A1/en unknown
- 2012-01-24 JP JP2013551282A patent/JP5998152B2/ja active Active
- 2012-01-24 AU AU2012209295A patent/AU2012209295B2/en active Active
- 2012-01-24 US US13/356,763 patent/US8691184B2/en active Active
- 2012-01-24 CA CA2825306A patent/CA2825306C/en active Active
- 2012-01-24 CN CN201280017060.3A patent/CN103562202B/zh active Active
- 2012-01-24 EP EP12739376.7A patent/EP2668180B1/en active Active
- 2012-01-24 WO PCT/US2012/022315 patent/WO2012103059A2/en not_active Ceased
- 2012-01-24 KR KR1020137021901A patent/KR101762724B1/ko active Active
- 2012-01-24 EP EP18186324.2A patent/EP3459945A1/en not_active Withdrawn
- 2012-01-24 ES ES12739376.7T patent/ES2693107T3/es active Active
-
2013
- 2013-07-23 ZA ZA2013/05571A patent/ZA201305571B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014507421A5 (https=) | ||
| JP2016506916A5 (https=) | ||
| JP2019524883A5 (https=) | ||
| JP2012515776A5 (https=) | ||
| JP2015532295A5 (https=) | ||
| JP2013510120A5 (https=) | ||
| JP2012532137A5 (https=) | ||
| JP2016040288A5 (https=) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2013537203A5 (https=) | ||
| RU2018105549A (ru) | Производные бензодиазепина как ингибиторы rsv | |
| JP2017511360A5 (https=) | ||
| JP2012508252A5 (https=) | ||
| JP2014511840A5 (https=) | ||
| JP2013510123A5 (https=) | ||
| AR056186A1 (es) | Compuesto de imidazo[1,2-a]piridinilo, su uso para la fabricacion de un medicamento y formulacion farmaceutica que lo comprende | |
| JP2014518266A5 (https=) | ||
| JP2015517574A5 (https=) | ||
| JP2009535307A5 (https=) | ||
| JP2013512903A5 (https=) | ||
| RU2015143542A (ru) | Ингибиторы jak2 и alk2 и способы их использования | |
| JP2012512891A5 (https=) | ||
| JP2013508279A5 (https=) | ||
| JP2014515406A5 (https=) | ||
| JP2010524932A5 (https=) |